CompletedPhase 2NCT04908280

Study of Ruxolitinib Cream for the Treatment of Discoid Lupus Erythematosus

Studying Discoid lupus erythematosus

Last synced from ClinicalTrials.gov May 7, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: University of Rochester
Principal Investigator: Christopher T Richardson, MD, PhD, MD
University of Rochester
Intervention: Ruxolitinib(drug)
Enrollment: 10 enrolled
Eligibility: 18 years · All sexes
Timeline: 2022 – 2024

Study locations (1)

UR Medicine Dermatology College Town, Rochester, New York, United States

Collaborators

Incyte Corporation

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04908280 on ClinicalTrials.gov

Other trials for Discoid lupus erythematosus

Additional recruiting or active studies for the same condition.

RECRUITINGPHASE2NCT06261021
Study to Evaluate the Efficacy of Ruxolitinib 1.5% Cream in Adult Subjects with Discoid Lupus Erythematosus
Innovaderm Research Inc.

See all trials for Discoid lupus erythematosus →

← Back to all trials